Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| I'm proud of what our team accomplished in 2023 |
| In closing, our team is poised to deliver another strong year of financial performance and solid execution |
| As a result of our outstanding Q4, we entered 2024 with considerable momentum, which is reflected in our guidance |
| So far we've had excellent track record |
| The cash contribution from this divestiture strengthens our financial position and puts us on an even more solid path to profitability |
| We've been able to maintain a similar strength to other products |
| Our fourth quarter was very strong and I'm delighted to report that we have never been better positioned for success in our history as you will hear today |
| We believe these programs are part of what helped us achieve record revenues in the fourth quarter, so we are going to continue the training and over quota incentive programs while adding a new incentive target targeting balanced selling across our product lines |
| We're very confident that not only will the number of contracts grow, but our penetration will grow as well |
| We believe that that dynamic of the one plus one equaling three to four will benefit the whole portfolio |
| NIVIS represents an innovative, high quality wound healing product, and we expect it to perform even better as part of a portfolio of its acquirer |
| And then as the contracting, et cetera, starts to come into play, as this year goes forward and through next year, I think LIQUIFIX itself will start to become an excellent contributor in the business as well |
| Both products have been available and successful in European markets for more than three years |
| For the full year the gross margin improvement was driven by improved inventory management processes and lower amortization of intangible assets |
| We made exceptional progress in expanding awareness around the OviTex and OviTex PRS portfolio and the efficacy of our mesh in optimizing clinical outcomes and soft tissue preservations |
| PRS revenues grew 75% year-over-year year versus 34% for the hernia products and we expect this pattern to continue given that PRS is the more recently launched product line |
| We think that's very, very attainable |
| Congrats on a really strong finish to the year |
| I'll note that this is the 12th consecutive quarter we've had at least 35% year-over-year top line growth with an average growth rate over those twelve quarters of 49% |
| As Tony mentioned earlier, revenue for the fourth quarter of 2023 increased 46% year-over-year to $17 million and grew 41% for the year to $58.5 million, with OviTex growing 36% and OviTex PRS growing 51% for the year |
| As we've often said, we want to create a portfolio that drives growth, increases awareness, expands market share for products across our entire hernia franchise, and demonstrates our commitment to improving all aspects of hernia repair |
| It's a very good learning curve and tips and pearls for us to tap into |
| One of TELA's key differentiators is the compatibility of our reinforced biologic products with hernia procedures performed robotically and laparoscopically |
| We're really excited about the opportunity to bring LIQUIFIX to the U.S |
| And we expect that with the additional training that we're giving them, with the greater breadth of our regional managers now, who manage fewer reps individually, that they will be able to at least achieve the sorts of productivity curves that reps have in the past |
| Obviously you had a strong start or strong end of the year and typical medtech seasonality supports that |
| I would like to thank all those at TELA for their part in making 2023 such a success and setting us up for continued outstanding work in 2024 |
| It's going to be similar to tackers and staplers, and the margin will be at or better than depending on the exact ASP that we're able to achieve the rest of our portfolio |
| We've talked about some of the factors that drive the very strong fourth quarter and then are essentially pulling some revenue from the first quarter into the fourth quarter in the past, those are a couple of things |
| And we're really pleased to expose our company to our sales team, to this product, at the national sales meeting today |
| Statement |
|---|
| The slight decrease in the fourth quarter of 2023 versus the fourth quarter of 2022 was primarily due to an increase in our excess and obsolete inventory adjustments incurred during that period |
| We expect we will continue to see turnover in 2024, although at lower rates than in prior years and with little expected negative impact |
| Net loss was $12.9 million in the fourth quarter of 2023 compared to $10 million in the same period in 2022 |
| As we have said in the past, we expect operating loss and net loss to be less in 2024 than in 2023, even excluding the contribution from the divestiture of NIVIS |
| Loss from operations was $12.3 million in the fourth quarter of 2023 compared to $9.4 million in the prior year period |
| So that means that the first quarter is typically flat to slightly downish from the preceding fourth quarter, and then the quarters succeeding the first quarter grow from that, with a step up from the first to the second quarter typically being one of the larger incremental steps in the year |
| So I think given time, pressure, addition of clinical data, maturity of our commercial structure and team that we're slowly proving that we can penetrate into GPOs over the long haul |
| So we do expect, notwithstanding the leveling off of our sales force, that sort of seasonality to persist |
Please consider a small donation if you think this website provides you with relevant information